The treatment of advanced thyroid cancer has undergone rapid evolution in the last decade,
with multiple kinase inhibitor drug approvals for each subtype of thyroid cancer and a …

The endothelium can evoke relaxations of the underlying vascular smooth muscle, by
releasing vasodilator substances. The best‐characterized endothelium‐derived relaxing …

Preeclampsia, a systemic vascular disorder characterized by new-onset hypertension and
proteinuria after 20 weeks of gestation, is the leading cause of maternal and perinatal …

Cardiovascular disease is a major contributor to global morbidity and mortality and is the
common end point of many chronic diseases. The endothelins comprise three structurally …

Cancer therapies can lead to a broad spectrum of cardiovascular complications. Among
these, cardiotoxicities remain of prime concern, but vascular toxicities have emerged as the …

Since the late 1990s, there has been a steady decline in cancer-related mortality, in part
related to the introduction of so-called targeted therapies. Intended to interfere with a specific …

Abstract Sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally approved for type 2
diabetes mellitus, have demonstrated efficacy in reducing cardiovascular events, particularly …

In the United States alone, there are currently approximately 14.5 million cancer survivors,
and this number is expected to increase to 20 million by 2020. Cancer therapies can cause …

Cardiovascular diseases are a leading cause of morbidity and mortality in most developed
countries of the world. Pharmaceuticals, illicit drugs, and toxins can significantly contribute to …

The vascular endothelial growth factor (VEGF) signaling pathway (VSP) fulfills a cardinal
role in endothelial cells and its inhibition has profound cardiovascular impact. This is true not …